Frazier Healthcare Ventures (FHV) has never been one to faddishly follow the flow of money in or out of medical device investing. Founded in 1991 by Alan D. Frazier, former EVP and CFO of Immunex Corp., the Seattle, WA-based venture firm has, from its inception, stayed loyal to life science investing, including a significant focus on medical devices. FHV has continued to invest actively in device start-ups during periods when other VCs abandoned them in favor of IT, telecommunications, or an exclusive focus on biotechnology.
What is relatively new at Frazier is that, in maintaining its commitment to dedicate roughly one-third of its life science portfolio to devices (with around 60% in biotech and the rest in health care IT and services), it's decided to place an emphasis on earlier stage deals
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?